Is "Strict" conventional therapy enough for the treatment of coronary artery disease?

Circulation Journal

Volumn 75, Issue 9, 2011, Pages 2046-2047

  Sakata, Yasuhiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ACUTE CORONARY SYNDROME; ALLOPATHY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; EDITORIAL; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CORONARY STENOSIS; FEMALE; HUMANS; MALE;

EID: 80052168632     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0858     Document Type: Editorial

References (12)

1. Current status of the background of patients with coronary artery disease in Japan. Circ J 2006; 70: 1256-1262.
2. Kohro T, Yamazaki T, Izumi T, Daida H, Kurabayashi M, Miyauchi K, et al on behalf of the JCADII Investigators. Intensively lowering both low-density lipoprotein cholesterol and blood pressure dose not reduce cardiovascular risk in Japanese coronary artery disease patients. Circ J 2011; 75: 2062-2070.
3. Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: Exactly how essential? J Am Coll Cardiol 2009; 54: 1827-1834.
4. Verdecchia P, Angeli F, Cavallini C, Mazzotta G, Garofoli M, Martire P, et al. The optimal blood pressure target for patients with coronary artery disease. Curr Cardiol Rep 2010; 12: 302-306.
5. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884-893.
6. de Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KA, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 2004; 292: 1307-1316.
7. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
8. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005; 294: 2437-2445.
9. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
10. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: A comparative meta-analysis of randomised controlled trials. Heart 2007; 93: 914-921.
11. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al; MUSASHI-AMI Investigators. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 2006; 97: 1165-1171.
12. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al. Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: Subanalysis of MUSASHI-AMI. Circ J 2007; 71: 1348-1353.